Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy

August 8th 2022

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

Bispecific Antibodies Represent Appealing Option for Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma

August 5th 2022

Amrita Krishnan, MD, discusses emerging data on bispecific antibodies, the exploration of the antibody-drug conjugate belantamab mafodotin, and the challenges of delivering CAR T-cell therapy in the right setting to the appropriate patients with multiple myeloma.

Dr. Tilly on Pola-R-CHP in an Asia Subpopulation of Patients With DLBCL

August 5th 2022

Hervé Tilly, MD, PhD, discusses the efficacy of polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone in an Asia subpopulation of patients with diffuse large B-cell lymphoma.

Dr. Maude on Safety of Tisagenlecleucel in Pediatric B-ALL

August 5th 2022

Shannon L. Maude, MD, PhD, discusses notable long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

New Acalabrutinib Tablet Formulation Approved for Current Indications, Including CLL, SLL, and MCL

August 5th 2022

The FDA has approved a new tablet formulation of acalabrutinib for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and for those with relapsed or refractory mantle cell lymphoma.

Azacitidine/Quizartinib Combo Showcases Early Activity in MDS, MDS/MPN With FLT3 or CBL Mutations

August 5th 2022

The combination of azacitidine and quizartinib produced preliminary responses in patients with myelodysplastic syndrome and myelodysplastic syndrome/myeloproliferative neoplasms whose tumors harbored FLT3 or CBL mutations, according to data from a phase 1/2 trial (NCT04493138).

Dr. Leleu on the Future of Later-Line Therapy in Multiple Myeloma

August 4th 2022

Xavier Leleu, MD, PhD, discusses how the declining prognosis of patients with multiple myeloma correlates with line of therapy and time after diagnosis, highlighting an unmet need for more effective later-line therapies in this population.

Use of Romiplostim in Chronic Immune Thrombocytopenia

August 4th 2022

Considerations for the uptake and use of romiplostim, an injectable thrombopoietin receptor agonist, in immune thrombocytopenia.

Data on Avatrombopag in Chronic ITP

August 4th 2022

A commentary on clinical experience with avatrombopag, another oral TPO-RA, in treating ITP.

Ropeginterferon Alfa-2b Proves to be Efficacious, Safe in Japanese Patients with Polycythemia Vera

August 2nd 2022

Ropeginterferon alfa-2b produced durable complete hematologic responses without phlebotomy and showcased a consistent safety profile in Japanese patients with polycythemia vera, according to findings from a phase 2 study (NCT04182100) presented during the 2022 EHA Congress.

FDA Grants Priority Review to Omidubicel for Blood Cancers Requiring Transplant

August 1st 2022

The FDA has accepted a priority review of a biologics license application for omidubicel as a treatment for patients with blood cancers in need of allogenic hematopoietic stem cell transplant.

Identifying the Role of the Microbiome in HSCT and GVHD

August 1st 2022

Expert panelists review the role of the microbiome in the context of hematopoietic stem cell transplantation and steroid-refractory acute GVHD.

Steroid-Refractory GVHD: Enrolling Patients on Clinical Trials

August 1st 2022

Key opinion leaders highlight the value of clinical trials and share their perspective on enrolling patients in the setting of acute GVHD.

Fixed-Duration Venetoclax/Obinutuzumab Provides Robust PFS Benefit in Untreated CLL

July 29th 2022

Othman Al-Sawaf, MD, discusses the 5-year follow-up data of the phase 3 CLL14 trial and emphasized the importance of fixed-duration treatments in high-risk patients with chronic lymphocytic leukemia.

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 28th 2022

Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103), and the effect of the approval on academic and community center practice patterns.

A Closer Look at CAR T-Cell Therapy Clinical Trial Design

July 28th 2022

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.

Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL

July 28th 2022

Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.

Sylvester Experts Explain the Most Promising Advances in Cancer Research and Treatment Presented at ASCO 2022

July 28th 2022

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

Eltrombopag in Chronic Immune Thrombocytopenia

July 28th 2022

Expert panelists consider clinical trial data on and personal experience with using eltrombopag, an oral TPO-RA, in immune thrombocytopenia.

Selecting an Oral TPO-RA for Chronic Immune Thrombocytopenia

July 28th 2022

A brief discussion of factors that influence selection of oral versus injectable TPO-RA therapy for ITP.